Isofol Medical AB (OSTO:ISOFOL) Interest Expense : kr0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Isofol Medical AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Isofol Medical AB's interest expense for the three months ended in Mar. 2024 was kr 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was kr0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Isofol Medical AB's Operating Income for the three months ended in Mar. 2024 was kr -9.68 Mil. Isofol Medical AB's Interest Expense for the three months ended in Mar. 2024 was kr 0.00 Mil. Isofol Medical AB has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Isofol Medical AB Interest Expense Historical Data

The historical data trend for Isofol Medical AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB Interest Expense Chart

Isofol Medical AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.18

-0.15

-0.17

Isofol Medical AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-0.01	-	0.05	-

Isofol Medical AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.04 Mil.

Isofol Medical AB (OSTO:ISOFOL) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Isofol Medical AB's Interest Expense for the three months ended in Mar. 2024 was kr0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was kr-9.68 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was kr0.00 Mil.

Isofol Medical AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Isofol Medical AB had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Isofol Medical AB (OSTO:ISOFOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

5IU:Germany

Address

Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46

Website

http://www.isofol.se

Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (OSTO:ISOFOL) Headlines

No Headlines